Three US senators asked the Social Security Administration to respond to a report saying it reduced or suspended benefits for those who received COVID-19 relief payments; mifepristone, a drug taken to help manage miscarriages, remains widely unavailable to patients experiencing pregnancy loss; pharmaceutical companies are beginning trials to get weight-loss shots approved for patients with obesity 6 years and older.
Three US senators asked the Social Security Administration (SSA) to respond to a news report that said it reduced or suspended the benefits of people who received COVID-19 relief payments, according to . KFF Health News reported that the COVID-19 relief payments totaling as much as $3200 per person led the SSA to claw back other federal benefits, like monthly support payments for those impoverished, disabled, or aged 65 years or older. Also, the SSA sent notices to some people receiving Supplemental Security Income benefits who had more money than the $2000 asset limit due to COVID relief that alleged they were overpaid, asking them to repay the government; in some cases, SSA cut off benefit payments. The senators’ letter requested answers to a list of questions within 30 days.
Mifepristone, a drug taken almost exclusively to induce abortions or manage miscarriages, is tightly regulated by the federal and state governments and remains widely unavailable to patients experiencing pregnancy loss, according to Stateline. The American College of Obstetricians and Gynecologists recommended the use of both mifepristone and misoprostol to aid in passing pregnancy tissue, but a study revealed that only 1% of patients received the recommended 2-drug protocol due to mifepristone restrictions. These restrictions resulted in disparities in miscarriage care nationwide, even affecting states without abortion restrictions, as mifepristone is only available at hospitals, health clinics, and doctors’ offices that routinely provide abortions. Also, federal law requires all patients who receive the drug to sign a form acknowledging their desire to end their pregnancy, even if they experienced a miscarriage. Efforts to increase mifepristone access for miscarriage care are being opposed by anti-abortion groups who feel it is part of a larger campaign to make it more available for elective abortion.
Pharmaceutical companies are conducting trials in an attempt to get weight-loss shots approved for patients 6 years and older with obesity, according to Bloomberg. Eli Lilly & Co is planning to test its diabetes drug tirzepatide (Mounjaro), and Novo Nordisk A/S is planning to test (liraglutide) Saxenda, in patients as young as 6. If either drug is approved, it would be the first glucagon-like peptide-1 receptor agonists available to patients that young anywhere in the world, as the FDA and the European Medicines Agency have only greenlit them in adolescents 12 and older thus far. Pediatric obesity experts say the availability of these medications is a game-changer, as according to the CDC, about 20% of children 6 and older are obese. For pharmaceutical companies, making these medications available to a younger demographic has a huge financial upside. Despite these benefits, it is currently unclear how widely the medications would be used.
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Interactive mHealth App Helped Improve Patients’ Lifestyle Habits After Undergoing PCI
April 29th 2024These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
UK Study: Most Patients With MG Require Hospitalization, Driving Health Care Resource Use
April 27th 2024Over a median follow-up time of nearly 3 years, three-fourths (72.8%) of patients with myasthenia gravis (MG) were hospitalized and half visited the accident and emergency department.
Read More
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More